International Journal of Infectious Diseases 15 (2011) e747–e752
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
journal homepage: www.elsevier.com/locate/ijid
Effect of biofilm formation on the excretion of Salmonella enterica serovar
Typhi in feces
Abida Raza a, Yasra Sarwar b, Aamir Ali b, Amer Jamil c, Asma Haque b, Abdul Haque b,*
a
Molecular Diagnostics and Research Laboratory, Nuclear Medicine, Oncology and Radiotherapy Institute, Islamabad, Pakistan
Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering (NIBGE), PO Box 577, Jhang Road, Faisalabad, Pakistan
c
Department of Biochemistry, University of Agriculture Faisalabad, Pakistan
b
A R T I C L E I N F O
S U M M A R Y
Article history:
Received 11 November 2010
Received in revised form 25 March 2011
Accepted 6 June 2011
Objectives: We hypothesized that Salmonella enterica serovar Typhi (S. Typhi) with higher biofilm and
capsule production capability are more able to survive continuously in typhoid patients/carriers, with
subsequent prolonged shedding in feces.
Methods: Bacterial cell release from biofilm (produced in vitro and confirmed by specific staining and
electron microscopy) and comparative cytotoxicity were studied on Caco2 cells. Functionality of the
biofilm diffusion barrier was tested against ciprofloxacin. Biofilm production was graded and semiquantified as , +, ++, +++, and ++++.
Results: Out of 30 isolates, 23 produced biofilm. The average post-treatment detection of S. Typhi in
blood was 7–13 days and in stool was 13–32 days. A fall in cell count from 104 to approximately 101 over
the course of 3 days as compared to total elimination of planktonic cells in 16 h after ciprofloxacin
application substantiated the protective role of biofilm. Lactic dehydrogenase release ranged from 38% in
non-biofilm producers to 97% in the highest biofilm producers, indicating increased pathogenic
behavior.
Conclusions: The period of S. Typhi clearance from typhoid patients after recovery was found to be
directly related to biofilm production capability.
ß 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Corresponding Editor: Craig Lee, Ottawa,
Canada
Keywords:
Typhoid carriers
Biofilm
Salmonella enterica serovar Typhi
1. Introduction
Bacterial biofilms are the predominant mode of bacterial
growth, reflected in the observation that approximately 80% of all
bacterial infections are related to biofilms.1,2 Biofilms are defined
as structured communities of bacterial cells enclosed in a selfproduced polymeric matrix adherent to inert or living surfaces.3–5
Salmonella enterica serovar Typhi (S. Typhi), the causative agent
of typhoid in humans, is also capable of producing biofilms; this
contributes to its resistance and persistence in the host. S. Typhi is
transmitted through the fecal–oral route by contaminated water
and food. Typhoid is communicable for as long as the infected
person is capable of excreting bacteria in stool. These bacteria
usually disappear from the stool about a week after symptoms of
illness have resolved. However, a percentage of these infections
can result in asymptomatic carriage of salmonellae, possibly due to
the formation of biofilms as a mechanism that contributes to the
development of the carrier state.6
* Corresponding author. Tel.: +92 41 2651475/79 ext. 240; fax: +92 41 2651472.
E-mail address: ahaq_nibge@yahoo.com (A. Haque).
Bacteria in biofilms are generally considered well protected
against environmental stresses, antibiotics,7 disinfectants, and the
host immune system,8 and as a consequence are extremely
difficult to eradicate.9 Planktonic Salmonella populations are found
to be sensitive to different antibiotics as compared to biofilms. It is
reported that Salmonella enterica serovar Typhimurium biofilms
pre-formed on microplates are up to 2000-fold more resistant to
ciprofloxacin as compared to planktonic cells.10 This is particularly
concerning, as ciprofloxacin is commonly used to treat Salmonella
infections.11
Traditionally, the ability of S. Typhi to cause disease and to
induce a protective immune response is attributed to possession of
a capsule that is polysaccharide in nature. Yet it is also well known
that S. Typhi can cause disease in the absence of capsule.12,13 As
biofilm has a protective role similar to capsule, we hypothesized
that its presence may have a shielding role and be a basis for longer
survival in the body, thus substantiating the carrier status.
This study was designed to evaluate the possible role of biofilm
produced by S. Typhi on delayed clearance of bacteria (extended
carrier state) from the body in association with the presence of the
outer capsular polysaccharide, and the comparative efficacy of
anti-typhoidal drugs, especially ciprofloxacin, against planktonic
and biofilm phase bacteria.
1201-9712/$36.00 – see front matter ß 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.ijid.2011.06.003
e748
A. Raza et al. / International Journal of Infectious Diseases 15 (2011) e747–e752
2. Materials and methods
2.1. Clinical samples
Clinically suspected cases of typhoid (both sexes; age range 8–
55 years) with a fever of 3–20 days duration and most of the
following symptoms were studied: enlarged spleen, headache,
rose spots, malaise, abdominal discomfort, lethargy, constipation
followed by diarrhea, fatigue, delirium, and agitation. One
hundred patients who were PCR-positive (targeting the fliC gene)
and were due to receive standard typhoid treatment were
included. Clinical specimens were collected on the same day or
within 1–2 days after the first consultation. Series of blood and
stool samples were collected (twice a week) from each patient
until the PCR became negative for at least two consecutive
collections. Blood samples were collected simultaneously in
potassium EDTA (20 mM) BD Vacutainer for PCR and in sterilized
tryptic soy broth (TSB) for blood culture (1:8), while stool samples
were collected in sterile containers containing glycerol saline
buffer (dipotassium phosphate 22.7 mM (3.1 g/l), monopotassium phosphate 7 mM (1 g/l), phenol red (0.003 g/l), sodium
chloride 72 mM (4.2 g/l)). Samples that were blood culturepositive (28 out of 100) and identified as S. Typhi by conventional
biochemical and molecular methods,14,15 were selected for
further study. These isolates were subcultured in TSB overnight,
and tested for Vi antigen by corresponding antiserum (Bio-Stat,
UK); aliquots were preserved in 20% glycerol and stored at 20 8C
until further use. When required, an aliquot of the stored S. Typhi
isolate was revived in TSB for 24 h at 37 8C.
2.2. Polymerase chain reaction (PCR)
DNA was extracted from blood as described previously.16
Briefly, 1 ml of blood containing 20 mM potassium EDTA as
anticoagulant was centrifuged at 10 000 rpm (Sorvall Legend RT)
for 5 min. Plasma was separated for serology. The pellet was
resuspended in 1 ml of lysis buffer (0.2% Triton X-100 in Tris–HCl
(pH 8.0)). The mixture was gently aspirated several times to
encourage efficient hemolysis. The tube was centrifuged at
12 000 rpm (Sorvall Legend RT) for 6 min, the supernatant was
discarded, and the procedure was repeated. The pellet was washed
with distilled water. The supernatant was removed, and the pellet
was subsequently resuspended in 20–30 ml of distilled water. The
tubes were sealed and then sterilized in boiling water for 20 min.
Extraction of bacterial DNA from fecal samples was performed
according to Frankel et al.17
Molecular detection of S. Typhi was done targeting the fliC gene
by regular primers ST1 50 -TATGCCGCTACATATGATGAG-30 and ST2
50 -TTAACGCAGTAAAGAGAG-30 , and nested primers ST3 50 -ACTGCTAAAACCACTACT-30 and ST4 50 -TGGAGACTTCGGTCGCGTAG-30 ;15
conditions have been described previously.18 The viaB operon, and
type IV B pili, which are essential for capsule formation and
bacterial attachment, were detected in all S. Typhi isolates by
targeting the tviA and pilS genes, respectively.19 Two reference
strains NIB25 and NIB38,19 were used as negative and positive
controls, respectively, for both the viaB operon and type IV B pili.
Oligonucleotides and enzymes used in the study were supplied by
Fermentas (Maryland, USA). Amplicons were separated on a 2%
agarose gel at 100 V for 60 min and photographed using Gel
DocTM-XR imaging system (Bio-Rad Laboratories, Inc., Hercules,
CA, USA).
2.3. Biofilm production by S. Typhi
After detection and confirmation of S. Typhi isolates and
evaluation of their Vi status with PCR, we followed the reported
methodology for the production of biofilms.20 However, as
adherence test medium (ATM) failed to produce biofilm, we used
modified biofilm production medium, which was optimized to
contain 60 mM NaCl, 20 mM KCl, 110 mM glucose, 30 mM
Na2HCO3, 20 mM NH4Cl, 40 mM K2HPO4, 50 mM (NH4)H2PO4,
1 mM CaCl2, 980 mM MgCl2, 86 mM FeCl3, and 40 mM Na2SO4. The
suspension was placed in grease-free sterilized sealed test tubes in
triplicate and incubated with mild shaking (170 rpm) at 37 8C for
24 h. For semi-quantitative grading we developed a reference that
subdivided the S. Typhi isolates into five categories, ranging from
no biofilm production ( ) to maximum biofilm production (++++).
2.4. Crystal violet staining of biofilm
Crystal violet staining of biofilm was done following the
methodology described elsewhere.21 Briefly, planktonic phase
cells were aspirated and biofilm ring was washed with a
continuous spray of 1 phosphate buffered saline (PBS; pH 6.8)
and incubated at room temperature for 1 h to fix the cells. Crystal
violet (1% in isopropanol–methanol–1 PBS; 1:1:18) was poured
into each test tube. Test tubes were incubated for 15 min at room
temperature and washed thoroughly with 1 PBS (pH 6.8) until
the buffer ran clear. Biofilm was then immersed in 33% acetic acid
to extract the dye. Dye retained by the bacterial cells was measured
at 570 nm. For quantification, a standard graph of crystal violet in
33% acetic acid was made. Dye retained by the bacterial cells was
measured at 570 nm in batches of six.
2.5. Transmission electron microscopy (TEM) of biofilm
Samples from the interface, planktonic phase, and TSB were
analyzed using TEM (Jeol 1010, Japan). For micro-encapsulation
method, agar (3%) blocks with biofilm samples were prepared,
thinly sliced, and studied under TEM. Direct analysis of biofilm
matrix on AEI carbon-coated grids was done. Bacterial biofilm
suspension was placed onto the grid and the bacteria were allowed
to adhere for 2 min and then fixed for 1 min with 1.5%
glutaraldehyde in sodium cacodylate buffer (100 mM, pH 7.4).
The grids were rinsed twice with water and negatively stained
with 0.75% (wt/vol) uranyl acetate (pH 6.4) for 1 min. The grids
were drained and subjected to microscopic studies.
2.6. Antibiotic susceptibility assay
Four commonly used antibiotics for typhoid were employed to
compare susceptibility patterns of biofilm resident and planktonic phase bacteria. Pieces of biofilm were cultured in 5 ml TSB
overnight, whereas for planktonic bacteria, 50 ml of inoculated
medium from the same tube was added to 5 ml of TSB and
incubated overnight. The antimicrobial susceptibility patterns
were determined as per the Clinical and Laboratory Standards
Institute (CLSI) recommendations,22 using the following commercial antimicrobial disks (HiMedia, India): chloramphenicol
(30 mg), ampicillin (10 mg), ciprofloxacin (5 mg), and trimethoprim (30 mg).
2.7. Ciprofloxacin penetration assay
Biofilm was exposed to 1 mg/ml of ciprofloxacin. Planktonic
phase cells were also transferred, essentially without dilution, into
fresh antibiotic-containing growth medium. Colony count experiments were performed in parallel. For the penetration assay,
biofilm produced was exposed to ciprofloxacin for specified time
intervals of 4, 8, 12, 16, 20, 24, 36, 48, 60, and 72 h. After exposure
to ciprofloxacin, the biofilm gummy material was used for colony
count experiments.
e749
A. Raza et al. / International Journal of Infectious Diseases 15 (2011) e747–e752
Table 1
LDH release assay for cytotoxicity after exposure to ciprofloxacin (1 mg/ml)
Cytotoxicity of escapers
Ciprofloxacin penetration
LDH release (A490/655)
% Cytotoxicity
% Bactericidal activity
Control (media)
Control (Triton X)
Control positive (free S. Typhi culture)
0.16 0.04
1.55 0.31
1.48 0.40
Taken as 100%
100% after 16 h
After (h):
4
8
12
16
20
24
36
48
60
72
1.11 0.03
0.98 0.23
0.81 0.05
0.83 0.02
0.75 0.3
0.78 0.04
0.71 0.31
0.60 0.41
0.48 0.05
0.41 0.08
74.65
60.95
55.47
56.84
52.73
47.94
47.26
39.04
30.13
27.39
30
40
52
60
65
63
79
85
88
94
LDH, lactate dehydrogenase.
2.8. Lactate dehydrogenase (LDH) assays
We used the increase in LDH release to show if S. Typhi cells in
biofilm are more pathogenic than planktonic cells. Human colon
epithelial cell line Caco2 was used for the assessment of LDH
release.23 Caco2 cells ATCC (Rockville, MD, USA) were grown in
Dulbecco’s modified Eagles medium (DMEM) as monolayers and
trypsinized. Viability counts were done by trypan blue (0.4%)
staining to assess the suitability for further experimentation.23
Biofilm was produced in a 96-well plate, and 200 ml of Caco2 cell
suspension was added for selected time periods (4, 8, 12, 16, 20, 24,
36, 48, 60, and 72 h, Table 1). The cell suspension was aspirated
after a specified time and centrifuged (3000 g, 5 min) to remove
debris. A 0.1-ml aliquot was dispensed into a 96-well microtiter
plate, and 0.1 ml/well of LDH substrate was added. Plates were
read after 10 min of incubation at room temperature using a plate
reader (Bio-Rad, Hercules, USA) at 490/655 nm. For the purpose of
calculating cytotoxicity values, background LDH release from
tissue culture cells was considered as low (media) control and
Triton-X 100 (0.01%) treated cells as high control. The experiment
was performed with high-grade biofilm producing S. Typhi isolates
in batches of eight.
2.9. Statistical analysis
Analysis of variance was used to determine the differences among
all four biofilm groups (high, medium, low, and non-biofilm
producers). The Tukey test was applied to check the differences
between each two of the biofilm groups, and the mean difference
was considered as significant at the 0.05 level. Data were analyzed
using statistical software SPSS version 16 (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Biofilm production
Forty percent (12/30) of the isolates were able to produce a high
level of biofilm (grade ++++ and +++), 16.7% (5/30) medium (++),
20% (6/30) low grade (+), and 23.3% (7/30) were unable to produce
biofilm (Figure 1). These results included the reference strains.
3.2. Biofilm matrix analysis
Electron microscopy confirmed the presence of biofilm matrix
(Figure 2). Cells were found to be embedded in the form of macrocolonies at the interface (Figure 2A) as compared to planktonic
phase cells in the middle of the test tube (Figure 2B). The biofilm,
which appeared as a slimy whitish gunk to the naked eye, was
observed as multicellular communities attached by water channels
that are represented by thread-like structures in TEM images.
Without shaking no biofilm was produced; only aggregation in the
middle of the test tube was observed. An increase in polysaccharide formation was observed after 24 h. Crystal violet staining
confirmed the biofilm production.
3.3. Biofilm production phenomenon in relation to clearance of S.
Typhi from the body
Figure 1. In vitro glass adherence test for Salmonella Typhi biofilm production.
Biofilm production reference for S. Typhi isolates: 24 h growth in modified biofilm
production medium at 170 rpm at 37 8C. Biofilm production was graded (from left
to right) as ++++, +++, ++, +, and , respectively.
Post-treatment, the last day of S. Typhi detection in blood
ranged from 10–15 days (mean 13.125 1.96) in high biofilm
producers to 7–15 days (mean 9.8 3.27) in medium producers, 8–
11 days (mean 8.88 1.21) in low-grade producers, and 5–10 days
(mean 6.85 1.67) in non-biofilm producers. Similarly, the last day of
detection of S. Typhi in feces had a mean value of 32.25 12.78 days
in high-grade biofilm producers, 23.6 7.5 days in moderate biofilm
producers, 16.51 2.13 days in low biofilm producers, and
13.28 2.81 days for non-biofilm producers, indicating a role of
biofilm production in the carrier state.
Regarding days to detect the S. Typhi in blood, the comparison of
high biofilm producers with low and non-biofilm producers showed
a significant difference (p = 0.04 and p < 0.001 respectively), while
the difference among all other biofilm groups was found to be
non-significant (p > 0.05). In the case of detection from stool, only
e750
A. Raza et al. / International Journal of Infectious Diseases 15 (2011) e747–e752
3.6. Ciprofloxacin penetration assay
Evidence for persisters was further strengthened with the
ciprofloxacin penetration assay in which the drug was able to
penetrate into the biofilm reducing the cell count from 104 to
approximately 101 over the course of 3 days, although the free
bacteria were totally killed after 16 h of exposure at 1 mg/ml.
Penetration into biofilm was slow (killing almost 30% of cells in the
first 4 h and up to 94% after 72 h) (Table 1).
3.7. Virulence status of biofilm producers and non-producers
Of the 30 isolates, seven failed to give any amplification for the
tviA gene. All the high-grade biofilm producers produced the
desired amplicon; among medium and low biofilm producers 4/5
and 4/6 were tviA-positive, respectively. The pilS was detected in
all biofilm-producing isolates. The non-biofilm producers showed
variable results; out of seven isolates, three were found positive for
both tviA and pilS, whereas four failed to give any amplification for
both genes. Details are described in Table 2.
4. Discussion
Figure 2. Transmission electron micrographs of biofilm (Magnification 23 500).
(A) Biofilm producing Salmonella Typhi. (B) Non-biofilm producers.
the difference between high and non-biofilm producers was found
to be significant (p = 0.008), and the difference among all other
biofilm groups was found to be non-significant (p > 0.05). Details
are given in (Table 2).
3.4. Antibiotic susceptibility of biofilm and planktonic phase cells
Out of 30 isolates, 23 (76%) produced biofilm; 19 were found
resistant to one or more anti-typhoid drugs, i.e., chloramphenicol (Cm), ampicillin (A), trimethoprim (T), and ciprofloxacin (C).
Of the seven isolates that failed to produce biofilm, four were
found sensitive to all four antibiotics (Table 2). No difference
was found in the resistance patterns of the cells from biofilm
matrix and planktonic phase when tested against all four
antibiotics.
3.5. LDH assay for cytotoxicity
A marked difference in LDH release was observed between the
two categories. More LDH release, 62% to 97%, was observed in
isolates with a high-grade biofilm production level as compared to
non-biofilm producers (i.e., 38% to 57%), showing that biofilm
producers are more cytotoxic (Table 1). The LDH release assay was
also used to study the continuous escape of bacteria from biofilm
for different time intervals of 4 to 72 h. In the first 4 h, maximum
cytotoxicity (75%) was observed with more LDH release, which
decreased with time but did not reach 0% in 72 h, showing the
presence of cells (persisters) inside the biofilm (Table 1).
The LDH release from high biofilm producers was found to be
significantly higher than in low and non-biofilm producers
(p < 0.001). The difference between medium and non-biofilm
producers was also found to be significant (p = 0.008), while the
difference among all other biofilm groups was found to be nonsignificant (p > 0.05).
Typhoid is communicable for as long as the infected person
excretes S. Typhi in the feces. Despite major treatment and
prevention efforts, millions of new typhoid infections occur
worldwide each year. For a subset of infected individuals, S. Typhi
colonizes systemically, mostly in the gall bladder, and remains
long after symptoms subside, serving as a reservoir for the further
spread of the disease.24 The excretion in stool usually begins about
a week after the onset of illness and continues through
convalescence and for a variable period thereafter.25
Biofilm formation is likely to play a significant role in
establishing long-term colonization, and bacterial cells are
continuously shed for extended periods.6 In this study, we tried
to find a correlation between this carrier state and the biofilm
production capability of isolates, if any. We found that shedding of
S. Typhi in stool continued for a longer time in patients infected
with high-grade biofilm producers. The maximum period for
shedding of bacteria observed in this study was 50 days (average
32.25 days) post-infection in the case of high biofilm producers,
and this was usually not more than 17 days (average 13.28 days) in
the case of non-biofilm producers. The presence of biofilm in S.
Typhi may thus be related to the length of the carrier state in a
patient after recovery.
Although biofilm production prolonged the carrier state, it
remains to be evaluated whether this was due to the physical
protective effect or to the biofilm bacteria being more resistant as
compared to planktonic phase bacteria. Recently, 194 S. enterica
strains isolated from infected children were investigated for their
ability to form biofilms on silicone disks; these were compared
with corresponding planktonic forms for susceptibility to nine
antimicrobial agents. About 56% of the strains were able to form
biofilms.26 The biofilms showed increased antimicrobial resistance
to all antibiotics as compared to the planktonic bacteria, with the
highest resistance rates for gentamicin (90%) and ampicillin (84%).
Our findings also show that when the bacterial cells are detached
from biofilm, they show similar drug resistance patterns to the
planktonic phase cells. However, they were more cytotoxic as
shown by increased LDH release from target Caco2 cells.
Real-time penetration of ciprofloxacin dropped the cell number
from 104 to approximately 101 at 1 mg/ml, but it was not able to
eliminate 100% of the cells and left the persisters intact. This
finding is consistent with other reports regarding persisters.10
Once the antibiotic level drops, the persisters may multiply,
explaining the relapsing nature of biofilm infections.
e751
A. Raza et al. / International Journal of Infectious Diseases 15 (2011) e747–e752
Table 2
Individual characteristics of Salmonella Typhi isolates
No.
Isolate
Last day of
blood PCR
positivea
Last day of
stool PCR
positivea
Drug resistance
patternb
Biofilm
visual
grading
tviA gene
pilS gene
LDH release
1
2
3
4
5
6
7
8
9
10
11
12
ST1275
ST1389
ST1594
ST1403
ST1404
ST1413
ST1425
ST1430
NIB38
ST1004
1577
1670
15
13
12
14
10
11
12
10
15
10
15
15
30
15
40
33
15
50
20
14
30
15
30
45
Cm, T
A, T
A, Cm,
A
T
A, Cm
A, Cm,
A, Cm,
A, Cm,
A, Cm,
T
Cm
+++
++++
++++
++++
++++
++++
++++
+++
++++
+++
++++
++++
Present
Present
Present
Present
Present
Present
Present
Present
Present
Present
Present
Present
Present
Present
Present
Present
Present
Present
Present
Present
Present
Present
Present
Present
1.59
1.48
1.57
1.82
1.62
1.49
0.98
1.51
1.58
1.42
1.49
1.08
1671-S
1890-XP
1350-XZ
1420
H56
13.125 1.96
10–15
10
7
15
10
7
32.25 12.78
15–50
32
20
15
20
31
Present
Present
Present
Present
Present
1.47 0.23
0.98–1.82
1.38
1.42
1.39
0.99
1.10
1421
1422
1429
1876
1987
2534
9.8 3.27
7–15
10
9
11
8
9
11
23.6 7.5
15–32
17
18
15
20
17
14
Present
Present
Present
Present
Present
Present
1.25 0.197
0.99 –1.42
1.32
0.96
0.90
1.03
1.00
0.99
NIB25
1680-S
1681-S
1423
1424
1428
1431
8.88 1.21
8–11
6
5
10
6
8
7
6
16.51 2.13
14–20
12
10
16
17
13
15
10
6.85 1.67
5–10
13.28 2.81
10–17
Mean SD
Min–max
13
14
15
16
17
Mean SD
Min–max
18
19
20
21
22
23
Mean SD
Min–max
24
25
26
27
28
29
30
Mean SD
Min–max
T
T,
T,
T,
T,
C
C
C
C
Cm
T
A
A, Cm, T, C
T
Cm
A
-
++
++
++
++
++
+
+
+
+
+
+
Present
Present
Present
Absent
Present
Present
Present
Present
Present
Absent
Absent
1.03 0.14
0.90 –1.32
Cm
A
T
Absent
Present
Absent
Present
Present
Absent
Absent
Absent
Present
Absent
Present
Present
Absent
Absent
0.87 0.076
0.76–0.99
PCR, polymerase chain reaction; LDH, lactate dehydrogenase; SD, standard deviation.
a
Days were counted from the day the disease was diagnosed.
b
Cells grown in LB broth/cells from matrix/planktonic phase showed the same pattern: chloramphenicol (Cm), ampicillin (A), trimethoprim (T), ciprofloxacin (C).
The presence of the Vi antigen is also known to increase the
infectivity of S. Typhi and the severity of disease in volunteers.27,28
Like biofilm, the Vi capsule, being exopolysaccharide in nature,
may have a significant role in biofilm formation and persistence of
infection. But as our data suggest, the viaB operon is found in both
biofilm and non-biofilm producers and thus is not a significant
contributor to biofilm production.
The type IV B pilus of the enteropathogenic bacteria S. Typhi is a
major adhesion factor during entry of this pathogen into
gastrointestinal epithelial cells.29 In this study, detection of type
IV B pili in all biofilm producers strongly suggests its preliminary
role in biofilm production. Unfortunately animal models are not
successful for S. Typhi, which is a strict human pathogen, and in
vivo studies are difficult and often inconclusive. Therefore,
considering the difficulties regarding in vivo studies to show the
prolonged carrier state, our findings provide valuable information
in this regard.
In conclusion, it was found that the time to clearance of S. Typhi
from typhoid patients after recovery (as gauged by PCR on stool
samples) is directly related to biofilm production capability. The
period between blood and stool PCR negativity differs from patient
to patient and may extend up to 2 months. The presence of biofilm
does not alter the drug resistance profile of the bacteria, but
provides physical protection which results in delayed clearance
probably due to ‘persisters’. It was also found that the presence of
Vi capsule has no relevance to biofilm production, but that type IV
B pili have a significant effect.
Acknowledgements
We are indebted to the Director of the National Institute for
Biotechnology and Genetic Engineering, Faisalabad for providing
financial support for this project. We are also thankful to Dr Yousaf
Zafar, former Head, Plant Biotechnology Division of the same
institute for providing facilities for TEM. Cell culture work was
performed at The School of Pharmacy, University of London during
AR’s stay at The School of Pharmacy, University of London, UK.
Ethical considerations: The study was reviewed and approved by
the review boards of the participating institutes. Informed consent
was provided by all participants or their parents.
Conflict of interest: No conflict of interest to declare.
References
1. Davies D. Understanding biofilm resistance to antibacterial agents. Nat Rev Drug
Discov 2003;2:114–22.
e752
A. Raza et al. / International Journal of Infectious Diseases 15 (2011) e747–e752
2. Hall-Stoodley L, Stoodley P. Evolving concepts in biofilm infections. Cell Microbiol 2009;11:1034–43.
3. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of
persistent infections. Science 1999;284:1318–22.
4. Hall-Stoodley L, Hu FZ, Gieseke A, Nistico L, Nguyen D, Hayes J, et al. Direct
detection of bacterial biofilms on the middle-ear mucosa of children with
chronic otitis media. JAMA 2006;296:202–11.
5. Homoe P, Bjarnsholt T, Wessman M, Sorensen HC, Johansen HK. Morphological
evidence of biofilm formation in Greenlanders with chronic suppurative otitis
media. Eur Arch Otorhinolaryngol 2009;266:1533–8.
6. Reeve KE. Salmonella binding to and biofilm formation on cholesterol/gallstone
surfaces in the chronic carrier state. Undergraduate Honors Thesis. School of
Allied Medical Professions, The Ohio State University; 2010.
7. Hoiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of
bacterial biofilms. Int J Antimicrob Agents 2010;35:322–32.
8. Jensen PO, Givskov M, Bjarnsholt T, Moser C. The immune system vs. Pseudomonas aeruginosa biofilms. FEMS Immunol Med Microbiol 2010;59:292–305.
9. Burmolle M, Thomsen TR, Fazli M, Dige I, Christensen L, Homoe P, et al. Biofilms
in chronic infections – a matter of opportunity – monospecies biofilms in
multispecies infections. FEMS Immunol Med Microbiol 2010;59:324–36.
10. Tabak M, Scher K, Chikindas ML, Yaron S. The synergistic activity of triclosan
and ciprofloxacin on biofilms of Salmonella Typhimurium. FEMS Microbiol Lett
2009;301:69–76.
11. Parry CM, Threlfall EJ. Antimicrobial resistance in typhoidal and nontyphoidal
salmonellae. Curr Opin Infect Dis 2008;21:531–8.
12. Arya SC. Field effectiveness of Vi polysaccharide typhoid vaccine in the People’s
Republic of China. J Infect Dis 2002;185:845. author reply 845-6.
13. Wain J, House D, Zafar A, Baker S, Nair S, Kidgell C, et al. Vi antigen expression in
Salmonella enterica serovar Typhi clinical isolates from Pakistan. J Clin Microbiol
2005;43:1158–65.
14. Ewing WH. Edwards and Ewing’s identification of the Enterobacteriaceae.
Fourth ed. New York: Elsevier Science; 1986.
15. Song JH, Cho H, Park MY, Na DS, Moon HB, Pai CH. Detection of Salmonella typhi
in the blood of patients with typhoid fever by polymerase chain reaction. J Clin
Microbiol 1993;31:1439–43.
16. Haque A, Ahmed J, Qureshi JA. Early detection of typhoid by polymerase chain
reaction. Ann Saudi Med 1999;19:337–40.
17. Frankel G, Riley L, Giron JA, Valmassoi J, Friedmann A, Strockbine N, et al.
Detection of Shigella in feces using DNA amplification. J Infect Dis
1990;161:1252–6.
18. Haque A, Ahmed N, Peerzada A, Raza A, Bashir S, Abbas G. Utility of PCR in
diagnosis of problematic cases of typhoid. Jpn J Infect Dis 2001;54:237–9.
19. Baker S, Sarwar Y, Aziz H, Haque A, Ali A, Dougan G, Wain J. Detection of Vinegative Salmonella enterica serovar Typhi in the peripheral blood of patients
with typhoid fever in the Faisalabad region of Pakistan. J Clin Microbiol
2005;43:4418–25.
20. Solano C, Sesma B, Alvarez M, Humphrey TJ, Thorns CJ, Gamazo C. Discrimination of strains of Salmonella enteritidis with differing levels of virulence by an in
vitro glass adherence test. J Clin Microbiol 1998;36:674–8.
21. Prouty AM, Schwesinger WH, Gunn JS. Biofilm formation and interaction with
the surfaces of gallstones by Salmonella spp. Infect Immun 2002;70:2640–9.
22. National Committee for Clinical Laboratory Standards. Performance standards
for antimicrobial susceptibility testing. Fourteenth informational supplement.
Document M100-S14. Wayne, PA: NCCLS; 2004.
23. Korzeniewski C, Callewaert DM. An enzyme-release assay for natural cytotoxicity. J Immunol Methods 1983;64:313–20.
24. Gonzalez-Escobedo G, Marshall JM, Gunn JS. Chronic and acute infection of the
gall bladder by Salmonella Typhi: understanding the carrier state. Nat Rev
Microbiol 2011;9:9–14.
25. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. N Engl J Med
2002;347:1770–82.
26. Papavasileiou K, Papavasileiou E, Tseleni-Kotsovili A, Bersimis S, Nicolaou C,
Ioannidis A, Chatzipanagiotou S. Comparative antimicrobial susceptibility of
biofilm versus planktonic forms of Salmonella enterica strains isolated from
children with gastroenteritis. Eur J Clin Microbiol Infect Dis 2010;29:1401–5.
27. Hornick RB, Greisman SE, Woodward TE, DuPont HL, Dawkins AT, Snyder MJ.
Typhoid fever: pathogenesis and immunologic control. 2. N Engl J Med
1970;283:739–46.
28. Hone DM, Attridge SR, Forrest B, Morona R, Daniels D, LaBrooy JT, et al. A galE via
(Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in
humans. Infect Immun 1988;56:1326–33.
29. Balakrishna AM, Saxena AM, Mok HY, Swaminathan K. Structural basis of
typhoid: Salmonella typhi type IVb pilin (PilS) and cystic fibrosis transmembrane conductance regulator interaction. Proteins 2009;77:253–61.